Detail akcie Biofrontera online

Business Summary: Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Biofrontera AG revenues increased 25% to EUR32.2M. Net loss decreased 99% to EUR369K. Revenues reflect United States (Country) segment increase of 30% to EUR22.2M, Germany (Country) segment increase of 31% to EUR6.3M. Lower net loss reflects Equity Earnings -Before Taxes decrease of 84% to EUR7.3M (expense), Other Expenses decrease of 74% to EUR236K (expense).